| Resveratrol improves the anticancer effects of doxorubicin in vitro and in vivo models: A mechanistic insight G Rai, S Mishra, S Suman, Y Shukla Phytomedicine 23 (3), 233-242, 2016 | 119 | 2016 |
| Sulfur alleviates arsenic toxicity by reducing its accumulation and modulating proteome, amino acids and thiol metabolism in rice leaves G Dixit, AP Singh, A Kumar, S Dwivedi, F Deeba, S Kumar, S Suman, ... Scientific Reports 5 (1), 16205, 2015 | 103 | 2015 |
| Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer S Mishra, AK Srivastava, S Suman, V Kumar, Y Shukla Cancer letters 369 (1), 67-75, 2015 | 96 | 2015 |
| New enlightenment of skin cancer chemoprevention through phytochemicals: in vitro and in vivo studies and the underlying mechanisms M Singh, S Suman, Y Shukla BioMed research international 2014, 2014 | 73 | 2014 |
| Current perspectives of molecular pathways involved in chronic inflammation-mediated breast cancer S Suman, PK Sharma, G Rai, S Mishra, D Arora, P Gupta, Y Shukla Biochemical and biophysical research communications 472 (3), 401-409, 2016 | 64 | 2016 |
| Anticoagulant and antioxidant activity of sulfated chitosan from the shell of donacid clam Donax scortum (Linnaeus, 1758) N Subhapradha, S Suman, P Ramasamy, R Saravanan, V Shanmugam, ... International Journal of Nutrition, Pharmacology, Neurological Diseases 3 (1 …, 2013 | 41 | 2013 |
| Metabolic fingerprinting in breast cancer stages through 1H NMR spectroscopy-based metabolomic analysis of plasma S Suman, RK Sharma, V Kumar, N Sinha, Y Shukla Journal of pharmaceutical and biomedical analysis 160, 38-45, 2018 | 39 | 2018 |
| Quantitative proteomics revealed novel proteins associated with molecular subtypes of breast cancer S Suman, T Basak, P Gupta, S Mishra, V Kumar, S Sengupta, Y Shukla Journal of proteomics 148, 183-193, 2016 | 38 | 2016 |
| Evaluation of growth inhibitory response of Resveratrol and Salinomycin combinations against triple negative breast cancer cells G Rai, S Suman, S Mishra, Y Shukla Biomedicine & Pharmacotherapy 89, 1142-1151, 2017 | 25 | 2017 |
| Characterization of biopolymer “chitosan” from the shell of donacid clam Donax scortum (Linnaeus, 1758) and its antioxidant activity A Shanmugam, N Subhapradha, S Suman, P Ramasamy, R Saravanan, ... Int. J. Pharm. Pharm. Sci 4, 460-465, 2012 | 24 | 2012 |
| Toxicoproteomics in human health and disease: an update S Suman, S Mishra, Y Shukla Expert review of proteomics 13 (12), 1073-1089, 2016 | 23 | 2016 |
| Phospho-proteomic analysis of primary human colon epithelial cells during the early Trypanosoma cruzi infection phase S Suman, G Rachakonda, SN Mandape, SS Sakhare, F Villalta, S Pratap, ... PLoS neglected tropical diseases 12 (9), 1-24, 2018 | 17 | 2018 |
| Autoantibodies against TYMS and PDLIM1 proteins detected as circulatory signatures in Indian breast cancer patients P Gupta, S Suman, M Mishra, S Mishra, N Srivastava, V Kumar, PK Singh, ... PROTEOMICS–Clinical Applications 10 (5), 564-573, 2016 | 16 | 2016 |
| Diallyl sulfide and its role in chronic diseases prevention S Suman, Y Shukla Drug Discovery from Mother Nature, 127-144, 2016 | 16 | 2016 |
| New enlightenment of skin cancer chemoprevention through phytochemicals M Singh, S Suman, Y Shukla vitro, 2014 | 13 | 2014 |
| Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy S Guan, S Suman, JM Amann, R Wu, DP Carbone, J Wang, MM Dikov Neoplasia 32, 100824, 2022 | 6 | 2022 |
| Current advances in breast cancer research: a molecular approach S Suman, G Suman, S Mishra Bentham Science Publishers, 2020 | 5 | 2020 |
| Ultraviolet radiation-induced immunomodulation: skin ageing and cancer G Suman, S Suman Skin Aging & Cancer: Ambient UV-R Exposure, 47-58, 2019 | 5 | 2019 |
| Improving combination therapies: targeting A2B-adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression JV Evans, S Suman, MUL Goruganthu, EE Tchekneva, S Guan, ... JNCI: Journal of the National Cancer Institute 115 (11), 1404-1419, 2023 | 2 | 2023 |
| 585 Phase 1 dose escalation trial of the selective A2B adenosine receptor antagonist PBF-1129 in patients with metastatic non-small cell lung cancer (mNSCLC) D Owen, L Wei, M Dikov, S Suman, R Wu, J Amann, C Schweitzer, ... Journal for ImmunoTherapy of Cancer 10 (Suppl 2), 2022 | 1 | 2022 |
Sanjay MishraResearch Scientist, OHIO STATE UNIVERSITYVerified email at osu.edu
